COVID-19: Viral Vectors Market (2020-2024)- Roadmap for Recovery | Rising Prevalence of Chronic Diseases to Boost the Market Growth | Technavio

LONDON–(BUSINESS WIRE)–Technavio has been monitoring the viral vectors market and it is poised to grow by USD 385.78 million during 2020-2024, progressing at a CAGR of almost 15% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. Technavio’s in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis. Download a Free Sample Report on COVID-19 Impacts

Frequently Asked Questions-

• Based on segmentation by application, which is the leading segment in the market?
• The gene therapy is expected to be the leading segment based on application in the global market during the forecast period.

• What are the major trends in the market?
• Emergence of novel technologies to manufacture viral vectors is one of the major trends in the market.

• At what rate is the market projected to grow?
• Growing at a CAGR of almost 15%, the incremental growth of the market is anticipated to be USD 385.78 million.

• Who are the top players in the market?
• Asklepios BioPharmaceutical Inc., Batavia Biosciences BV, Cobra Biologics Ltd., Creative Biogene, FinVector, Lonza Group Ltd., Merck KGaA, Novasep Holding SAS, Oxford Biomedica Plc, and Thermo Fisher Scientific Inc. are some of the major market participants.

• What are the key market drivers and challenges?
• Rising prevalence of chronic diseases is one of the major factors driving the market. However, the presence of stringent regulatory policies restraints the market growth.

• How big is the North America market?
• The North America region will contribute 60% of market growth.

The market is concentrated, and the degree of concentration will accelerate during the forecast period. Asklepios BioPharmaceutical Inc., Batavia Biosciences BV, Cobra Biologics Ltd., Creative Biogene, FinVector Oy, Lonza Group Ltd., Merck KGaA, Novasep Holding SAS, Oxford Biomedica Plc, and Thermo Fisher Scientific Inc. are some of the major market participants. The rising prevalence of chronic diseases will offer immense growth opportunities. To make most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Technavio’s custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations.

Viral Vectors Market 2020-2024: Segmentation

Viral Vectors Market is segmented as below:

• Application

• Geography
  • Asia
  • Europe
  • North America
  • ROW

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40121

Viral Vectors Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The viral vectors market report covers the following areas:

• Viral Vectors Market Size
• Viral Vectors Market Trends
• Viral Vectors Market Analysis

This study identifies the emergence of novel technologies to manufacture viral vectors as one of the prime reasons driving the viral vectors market growth during the next few years.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavio’s in-depth research has direct and indirect COVID-19 impacted market research reports.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio’s SUBSCRIPTION platform

Viral Vectors Market 2020-2024: Key Highlights

• CAGR of the market during the forecast period 2020-2024
• Detailed information on factors that will assist viral vectors market growth during the next five years
• Estimation of the viral vectors market size and its contribution to the parent market
• Predictions on upcoming trends and changes in consumer behavior
• The growth of the viral vectors market
• Analysis of the market’s competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of viral vectors market vendors

Table of Contents:

Executive Summary

Market Landscape

• Market ecosystem
• Market characteristics
• Value chain analysis

Market Sizing

• Market definition
• Market segment analysis
• Market size 2019
• Market outlook: Forecast for 2019 – 2024

Five Forces Analysis

• Five forces summary
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

Market Segmentation by Application

• Market segments
• Comparison by Application
• Gene therapy – Market size and forecast 2019-2024
• Vaccines – Market size and forecast 2019-2024
• Market opportunity by Application

Customer Landscape

Geographic Landscape

• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2019-2024
• Europe – Market size and forecast 2019-2024
• Asia – Market size and forecast 2019-2024
• ROW – Market size and forecast 2019-2024
• Key leading countries
• Market opportunity by geography
• Market drivers
• Market challenges
• Market trends

Vendor Landscape

• Vendor landscape
• Landscape disruption

Vendor Analysis

• Vendors covered
• Market positioning of vendors
• Asklepios BioPharmaceutical Inc.
• Batavia Biosciences BV
• Cobra Biologics Ltd.
• Creative Biogene
• FinVector
• Lonza Group Ltd.
• Merck KGaA
• Novasep Holding SAS
• Oxford Biomedica Plc
• Thermo Fisher Scientific Inc.

Appendix

• Scope of the report
• Currency conversion rates for US$
• Research methodology
• List of abbreviations

   

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.